{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:00Z","timestamp":1792786140763,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"CPRIT","award":["RP220542"],"award-info":[{"award-number":["RP220542"]}],"id":[{"id":"https:\/\/ror.org\/0003xa228","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Outcomes for upper gastrointestinal (UGI) cancers are poor except for those patients whose cancers are diagnosed at a very early stage. Unique socioeconomic factors may result in worse outcomes in the safety-net setting given that these patients often seek care later in the disease course. This study aims to understand the survival outcomes of patients with UGI cancers in a safety-net health care (SNH) setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients diagnosed with esophageal squamous (ES), esophageal adenocarcinoma (EA), and gastric carcinomas (G) at JPS Health Network in Fort Worth, Texas from January 1, 2018, to December 31, 2022, were identified in the tumor registry database. The electronic health record was queried for clinical characteristics, pathology variables, and management outcomes. Kaplan-Meier curve was used to illustrate the difference in survival time across cancer stages from an index date of diagnosis with censoring at date of last contact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 171 patients were included: the median age was 57 years, but 15 patients were under 40 years. By ethnicity, 40% were Hispanic. The majority were male (71%) and uninsured (65%). G was the most common primary site (n = 92, 54%), followed by EA (n = 58, 34%) and ES (n = 21, 12%). Of the 125 stage 4B patients, 69 (55%) did not receive any treatment, 6 received only palliative radiation, and the remainder received systemic therapy. In patients with stage 4B, the median overall survival for patients with systemic treatment was 7.9 months (95% CI: 6.7\u201311), compared with 2.1 months (95% CI: 1.5\u20133.0) without treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In an urban safety-net population with a high percentage of Hispanic population, most patients with advanced UGI cancers did not receive systemic therapy. Interventions to improve outcomes must consider the unique socioeconomic needs of this vulnerable population to translate clinical trial results into improved outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001287","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:00:48Z","timestamp":1766466048000},"page":"472-477","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Patients With Esophageal and Gastric Carcinoma at a Safety-net Health Care System"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4443-6457","authenticated-orcid":false,"given":"Kalyani","family":"Narra","sequence":"first","affiliation":[{"name":"JPS Oncology and Infusion Center, JPS Health Network, Fort Worth, TX"},{"name":"Department of Internal Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachita","family":"Guthula","sequence":"additional","affiliation":[{"name":"Texas College of Osteopathic Medicine, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari J.","family":"Teigen","sequence":"additional","affiliation":[{"name":"Office of Clinical Research, JPS Health Network, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Potti","sequence":"additional","affiliation":[{"name":"AdventHealth Cancer Institute, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolonda C.","family":"Bullock","sequence":"additional","affiliation":[{"name":"JPS Oncology and Infusion Center, JPS Health Network, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, TX"},{"name":"Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"e00745","DOI":"10.14309\/ctg.0000000000000745","article-title":"Racial, ethnic, and sex differences in incidence-based mortality of aggregate upper gastrointestinal cancers","volume":"15","author":"Malick","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/COC.0000000000001147","article-title":"Mortality patterns of esophageal cancer in the United States","volume":"48","author":"Kamal","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.14309\/01.ajg.0000951784.48398.f0","article-title":"5-year relative survival and mortality trends for esophageal carcinoma in the United States","volume":"118","author":"Li","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R6-20260923","first-page":"426","article-title":"Racial and ethnic disparities in incidence and mortality for the five most common gastrointestinal cancers in the United States","volume":"114","author":"Bui","year":"2022","journal-title":"J Natl Med Assoc"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1158\/1055-9965.EPI-20-0950","article-title":"Understanding racial disparities in gastrointestinal cancer outcomes: lack of surgery contributes to lower survival in African American patients","volume":"30","author":"Bliton","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/1055-9965.EPI-20-1808","article-title":"Reducing racial disparities in surviving gastrointestinal cancer will require looking beyond the fact that African-Americans have low rates of surgery","volume":"30","author":"H\u00e9bert","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1055-9965.EPI-23-0236","article-title":"Ethnic disparities in early-onset gastric cancer persist across rural-urban geographies","volume":"32","author":"Narasimman","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R10-20260923","first-page":"e61920","article-title":"Modifiable risk factors in hispanic adults with gastric cancer in the United States","volume":"16","author":"Domi\u0301nguez","year":"2024","journal-title":"Cureus"},{"key":"R11-20260923","first-page":"883","article-title":"Trends in esophageal cancer mortality and stage at diagnosis by race and ethnicity in the United States","volume":"32","author":"Corona","year":"2021","journal-title":"Cancer Causes Control"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet (London, England)"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R14-20260923","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet (London, England)"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"CheckMate 648 trial investigators. nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/ijc.35314","article-title":"Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: a real-world evidence study","volume":"156","author":"Slotman","year":"2025","journal-title":"Int J Cancer"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jso.26972","article-title":"Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: an US safety net collaborative analysis","volume":"126","author":"Macek","year":"2022","journal-title":"J Surg Oncol"},{"key":"R20-20260923","first-page":"542","article-title":"Health insurance status and cancer stage at diagnosis and survival in the United States","volume":"72","author":"Zhao","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1007\/s10620-014-3275-3","article-title":"Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992\u20132009 SEER data","volume":"59","author":"Lui","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"e2300269","DOI":"10.1200\/CCI.23.00269","article-title":"Extraction and imputation of eastern cooperative oncology group performance status from unstructured oncology notes using language models","volume":"8","author":"Xu","year":"2024","journal-title":"JCO Clin Cancer Informa"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet (London, England)"},{"key":"R27-20260923","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"R29-20260923","first-page":"e078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ (Clinical research ed)"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R31-20260923","doi-asserted-by":"crossref","first-page":"oyaf185","DOI":"10.1093\/oncolo\/oyaf185","article-title":"New tool in the toolbox: patient selection for zolbetuximab in advanced treatment-na\u00efve gastric\/gastroesophageal junction adenocarcinoma","volume":"30","author":"Grewal","year":"2025","journal-title":"Oncologist"},{"key":"R32-20260923","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jso.25299","article-title":"Identifying the barriers to gastric cancer care at safety-net hospitals: A novel comparison of a safety-net hospital to a neighboring quaternary referral academic center in the same healthcare system","volume":"119","author":"Zaidi","year":"2019","journal-title":"J Surg Oncol"},{"key":"R33-20260923","doi-asserted-by":"crossref","first-page":"e198577","DOI":"10.1001\/jamanetworkopen.2019.8577","article-title":"Comparison of 3 safety-net hospital definitions and association with hospital characteristics","volume":"2","author":"Popescu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R34-20260923","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1245\/s10434-019-08037-9","article-title":"Multidisciplinary teams improve gastric cancer treatment efficiency at a large safety net hospital","volume":"27","author":"Ju","year":"2020","journal-title":"Ann Surg Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0000000000001287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:00:25Z","timestamp":1790193625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0000000000001287"}},"subtitle":["A Juncture to Explore Disparities in Diverse Socioeconomic Cohorts and Ethnicities"],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001287","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2025-11-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}